Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AllerR
- Development stage
- Preclinical
- Lead developer
- HAL Allergy
- Modality
- Vaccines & Immunotherapeutics, Peptides
01
Overview
AllerR is an allergy vaccine candidate developed by the Swiss biopharmaceutical company Anergis. It is based on Anergis's proprietary Continuous Overlapping Peptides (COPs) technology, which is designed to create synthetic immunotherapies for allergies. AllerR was part of Anergis's pipeline assets intended for clinical development.
02
Targets
TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on AllerR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AllerR.